Category: Charles Fisher

  • AI startup Unlearn adds $50M for better, faster, smaller & cheaper clinical trials

    Unlearn.AI’s Series B round follows a positive European Medicines Agency draft opinion finding that the company’s artificial intelligence technology can be used in Phase 2 and Phase 3 clinical trials. The startup is now on the hunt for pharmaceutical partners that want to use the technology to speed up their clinical research.